Delta-Fly Pharma, Inc. (TYO:4598)

Delta-Fly Pharma Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	-1,623	-1,718	-1,426	-1,325	-964
Depreciation & Amortization	1	1	1	1	1
Other Operating Activities	-2	-3	-2	-2	5
Change in Accounts Payable	51	-82	117	20	3
Change in Other Net Operating Assets	16	-32	31	3	15
Operating Cash Flow	-1,557	-1,834	-1,279	-1,303	-940
Capital Expenditures	-	-	-1	-	-
Other Investing Activities	-	-	1	-	-
Long-Term Debt Issued	250	-	-	400	-
Long-Term Debt Repaid	-250	-	-	-400	-
Issuance of Common Stock	1,363	756	1,354	882	120
Other Financing Activities	-	-	499	-	-1
Financing Cash Flow	1,363	756	1,853	882	119
Foreign Exchange Rate Adjustments	-	-	-1	-3	-
Miscellaneous Cash Flow Adjustments	1	-	-1	-	1
Net Cash Flow	-193	-1,078	572	-424	-820
Free Cash Flow	-1,557	-1,834	-1,280	-1,303	-940
Free Cash Flow Margin	-	-	-	-	-313.33%
Free Cash Flow Per Share	-134.50	-208.41	-178.00	-229.96	-173.54
Cash Income Tax Paid	2	2	2	3	-2
Levered Free Cash Flow	-952.13	-1,193	-743.88	-806.88	-575.63
Unlevered Free Cash Flow	-952.13	-1,193	-743.88	-806.88	-575.63
Change in Working Capital	67	-114	148	23	18

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 1, 2026

Data Sources Report a data error